Fig. 1
From: The m6A reader IGF2BP2 promotes pancreatic cancer progression through the m6A-SLC1A5-mTORC1 axis
IGF2BP2 is positively correlated with SLC1A5 and is associated with poor prognosis of pancreatic cancer. A. Kaplan-Meier survival analysis based on glutamine score in TCGA-PDAC cohort (P < 0.0001, log-rank test). B. ROC curve and AUC of glutamine level in patients with pancreatic cancer. (ROC = receiver operator characteristic. AUC = area under curve). C. Correlation between mRNA expression of IGF2BP2 and glutamine metabolism-associated genes in the TCGA database. D. Correlation between mRNA expression of IGF2BP2 and SLC1A5 in the GEPIA database. E. GEPIA database showing that the expression of IGF2BP2 and SLC1A5 in PANCREATIC CANCER tissues (T) and normal pancreas tissues (N). F. GEPIA database showing that overall survival of pancreatic cancer patients with diverse IGF2BP2 and SLC1A5 expression. G. Immunohistochemistry staining of IGF2BP2 and SLC1A5 in human pancreatic cancer. Scale bar, 2000 μm 20 μm. H. Immunohistochemical score statistical analysis. I. Correlation between the expression of IGF2BP2 and SLC1A5 based on immune score. J. Immunohistochemistry staining for KPC mice pancreatic tissue. Scale bar, 50 μm. K. The protein expression of IGF2BP2 and SLC1A5 were measured by western blot in the nonmalignant hTERT-HPNE (HPNE) cells and pancreatic cancer cell lines (PaTu8988, Mia-PaCa2, SW1990, PANC-1, CFPAC, Aspc-1). L. Viability of HPNE cells, PANC-1 cells and PaTu 8988 cells with or without glutamine analyzed by the CCK8 assay. *P < 0.05, ****P < 0.0001